LCTX R&D Expense Growth
Lineage Cell Therapeutics, Inc. Common Stock · R&D Expense Growth
LCTX R&D Expense Growth
Latest reported42.15%period ending
LCTX FY R&D Growth (YoY) (0.00% → 42.15%)
Latest values, visible window
High-resolution chart · PNG
LCTX r&d expense growth history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 42.1504% | |
| -20.5858% | |
| 12.2828% | |
| -58.7574% | |
| 175.343% | |
| -31.374% | |
| -14.3498% | |
| -12.7747% | |
| -33.4626% | |
| -15.2521% | |
| 13.5119% | |
| 41.0501% | |
| 46.878% | |
| 32.2416% | |
| 73.5891% | |
| 165.8154% | |
| 74.0102% | |
| 76.2865% | |
| -31.9487% | |
| -6.7792% | |
| 35.8265% | |
| 24.3897% | |
| -18.1671% | |
| -34.5175% | |
| -49.8886% | |
| -31.3779% | |
| 188.2659% | |
| -19.0476% | |
| 0% | |
| -100% | |
| 125% | |
| 0% | |
| 0% | |
| 0% |